AbbVie to buy Stemcentrx in $5.8 billion deal

Drugmaker AbbVie said it would buy privately held oncology company Stemcentrx in a deal valued at $5.8 billion in cash and stock.

from Mergers and Acquisitions http://ift.tt/2391HJ8